Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/cpdd.345 http://scihub22266oqcxt.onion/10.1002/cpdd.345 C5697612!5697612!28409893     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Pharmacol+Drug+Dev 2017 ; 6 (6): 534-47 Nephropedia Template TP {{tp|p=28409893|t=2017. Spotlight on Anti?CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date |pdf=|usr=}}{{28409893}} gab.com Text Spotlight on Anti CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date JO: Clin Pharmacol Drug Dev http://www.kidney.de/pget.php?&tw=1&pmid=28409893 #FOAvip Migraine, a common neurovascular brain disorder, represents a severe and widespread health problem; along with medication?induced (medication?overuse) headache, it is the third?leading cause of disability worldwide. Currently, its therapeutic management remains unsatisfactory for several reasons; up to 40% of migraineurs are eligible for prophylactic treatment, but there are issues of efficacy, safety, and adherence. In recent years the evidence on the role of calcitonin gene?related peptide (CGRP) in migraine pathophysiology has been consolidated, so new and promising treatments for migraine pain and its possible prevention have been developed. The following review reports the results of the clinical trials conducted so far with each of the new monoclonal antibodies targeting CGRP or its receptor, with particular reference to safety, tolerance, and efficacy in migraine prevention. Moreover, the pharmacological characterization and further developments of each monoclonal antibody are reported, based on current knowledge. Twit Text FOAVip Spotlight on Anti CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date ????Clin Pharmacol Drug Dev http://www.kidney.de/pget.php?&tw=1&pmid=28409893 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28409893 #FOAvip English Wikipedia <ref>{{Cite pmid|28409893}}</ref> Spotlight on Anti?CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date #MMPMID28409893 Pellesi L; Guerzoni S; Pini LA Clin Pharmacol Drug Dev 2017[Nov]; 6 (6): 534-47 PMID28409893show ga Migraine, a common neurovascular brain disorder, represents a severe and widespread health problem; along with medication?induced (medication?overuse) headache, it is the third?leading cause of disability worldwide. Currently, its therapeutic management remains unsatisfactory for several reasons; up to 40% of migraineurs are eligible for prophylactic treatment, but there are issues of efficacy, safety, and adherence. In recent years the evidence on the role of calcitonin gene?related peptide (CGRP) in migraine pathophysiology has been consolidated, so new and promising treatments for migraine pain and its possible prevention have been developed. The following review reports the results of the clinical trials conducted so far with each of the new monoclonal antibodies targeting CGRP or its receptor, with particular reference to safety, tolerance, and efficacy in migraine prevention. Moreover, the pharmacological characterization and further developments of each monoclonal antibody are reported, based on current knowledge. äSpotlight on Anti?CGRP Monoclonal Antibodies in Migraine: The Clinical(epmc).pdf DeepDyve Pubget Overpricing